Study of VRN110755 for EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new oral targeted therapy (VRN110755) for people with EGFR-mutant lung cancer. It is for those whose cancer has advanced or spread, and who either have not been treated yet or who stopped responding to previous EGFR pills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older (19 in South Korea) and can swallow capsules.
- You have advanced or spread lung cancer with an EGFR gene change (mutation) found in a tissue or blood test.
- Your cancer either got worse after treatment with an EGFR pill, or you haven't had any treatment yet, depending on which group you join.
- You have at least one tumor outside your brain that can be measured on scans.
- You are generally up and about (ECOG 0 or 1) and agree to use birth control if needed.
- You do not have certain other gene changes like EGFR exon 20 insertion, active infections, unstable heart disease, or lung scarring.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, VRN101099, for people with HER2-positive or HER2-mutated cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow cancer growth.
This trial tests PLB1004, an oral medication that targets a specific gene mutation (EGFR) in non-small cell lung cancer. It may be an option if you have this mutation and are looking for a new treatment.
This study tests an oral pill (BPI-361175) for people with advanced non-small cell lung cancer that has specific EGFR mutations, especially when standard EGFR-targeted treatments are no longer working. The goal is to see if it can shrink tumors or slow growth.
This study tests an oral pill (DZD9008) that targets a specific genetic change in lung cancer called EGFR. If you have this mutation, the drug may shrink your tumor or slow its growth, especially if other treatments have stopped working or caused side effects.
This study tests a new targeted pill (YK-029A) versus standard chemotherapy as the first treatment for advanced lung cancer with a specific EGFR mutation. It aims to see if the targeted pill works better and has fewer side effects.
This trial tests a new drug, HSK40118, for people with advanced non-small cell lung cancer (NSCLC) that has an EGFR mutation and has been treated with certain EGFR-targeted therapies before. The goal is to see if this drug can help when other treatments stop working.
Hear when a new EGFR-Mutant Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.